Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 11/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | PRKDC | P78527 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.54 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188455 | 0.97 | PIK3CG (0.70) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL14932840 | 0.95 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL16091812 | 0.95 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188486 | 0.95 | PIK3CG (0.73) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188867 | 0.94 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL189527 | 0.93 | PIK3CG (0.73) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL13416099 | 0.93 | PIK3CG (0.65) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188823 | 0.92 | PIK3CD (0.65) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188812 | 0.92 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL189275 | 0.92 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| CN-103819416-A | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | EXELIXIS INC | 2014-05-28 | — | — | CN | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| CN-101282948-A | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | EXELIXIS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | PIK3CG 3/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | ERBB2, EGFR, ERBB3 | PIK3CG 328/4885PIK3CD 298/4885PIK3CA 79/4885 |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885PIK3CD 14/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.